Halozyme has technology licensing and collaboration agreements for our proprietary ENHANZE™ technology platform with Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly. These partnerships help fund our company through licensing fees, development and commercial milestones, and royalty payments.
With our lead oncology asset, PEGPH20, we seek nonclinical and clinical collaborations to study the pan-tumor potential. Currently, we have a partnership with Eisai to study PEGPH20 in breast cancer patients.
For more information on partnering with Halozyme, please contact a member of the Business Development Team.